Optimizing the "drug-Like" Properties of Leads in Drug Discovery - Couverture rigide

9780387340562: Optimizing the "drug-Like" Properties of Leads in Drug Discovery

Couverture rigide

ISBN 10 : 0387340564 ISBN 13 : 9780387340562

Editeur : Springer-Verlag New York Inc., 2006

Afficher les exemplaires de cette �dition comportant l'ISBN

2 D'occasion

De EUR 147,43

10 Neuf

De EUR 213,99

This book arises from a workshop organized by the American Association of Pharmaceutical Scientists entitled "Optimizing the Drug-Like Properties of Leads in Drug Discovery," which took place in Parsippany, NJ in September 2004. The workshop focused on the optimization of the drug-like properties of leads in drug discovery. The volume outlines strategies and methodologies designed to guide pharmaceutical and biotechnology companies through the drug discovery and development process.

Les informations fournies dans la section � Synopsis � peuvent faire r�f�rence � une autre �dition de ce titre.

�diteur: Springer-Verlag New York Inc.
Date d'�dition: 2006
Langue: anglais
ISBN 10: 0387340564
ISBN 13: 9780387340562
Reliure: Reli�
Nombre de pages: 522
�diteur: Borchardt Ronald, Kerns Edward, Hageman Michael, Thakker Dhrien, Stevens James
Coordonn�es du fabricant: GPSR Kontakt
ProductSafety@springernature.com

Uhlandstra�e 14
Stuttgart
70182
Allemagne

Acheter D'occasion

�tat : Satisfaisant

Afficher cet article

EUR 147,43

Exp�dition �EUR 4,30
Exp�dition nationale�: Etats-Unis

Ajouter au panier

Acheter neuf

Afficher cet article

EUR 213,99

Exp�dition �EUR 23
Exp�dition depuis Allemagne vers Etats-Unis

Ajouter au panier

R�sultats de recherche pour Optimizing the "drug-Like" Properties of Leads...

Image d'archives

Optimizing the "Drug-Like" Properties of Leads in Drug Discovery (Biotechnology: Pharmaceutical Aspects, IV)

Edit� par Springer, 2006

ISBN 10 : 0387340564 ISBN 13 : 9780387340562

Ancien ou d'occasion Couverture rigide

Vendeur : thebookforest.com, San Rafael, CA, Etats-Unis

�valuation du vendeur 4 sur 5 �toiles

Etat : Good. N� de r�f. du vendeur BAY21-00197

Contacter le vendeur

Acheter D'occasion

EUR 147,43

Exp�dition �EUR 4,30
Exp�dition nationale�: Etats-Unis

Quantit� disponible : 1 disponible(s)

Ajouter au panier

Image fournie par le vendeur

Optimizing the "Drug-Like" Properties of Leads in Drug Discovery

Ronald Borchardt

Edit� par Springer New York Aug 2006, 2006

ISBN 10 : 0387340564 ISBN 13 : 9780387340562

Neuf Couverture rigide

impression � la demande

Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne

�valuation du vendeur 5 sur 5 �toiles

Buch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book arises from a workshop organized by the American Association of Pharmaceutical Scientists entitled 'Optimizing the Drug-Like Properties of Leads in Drug Discovery,' which took place in Parsippany, NJ in September 2004. The workshop focused on the optimization of the drug-like properties of leads in drug discovery. The volume outlines strategies and methodologies designed to guide pharmaceutical and biotechnology companies through the drug discovery and development process. 524 pp. Englisch. N� de r�f. du vendeur 9780387340562

Contacter le vendeur

Acheter neuf

EUR 213,99

Exp�dition �EUR 23
Exp�dition depuis Allemagne vers Etats-Unis

Quantit� disponible : 2 disponible(s)

Ajouter au panier

Image d'archives

Optimizing the "Drug-Like" Properties of Leads in Drug Discovery (Biotechnology: Pharmaceutical Aspects, IV)

Edit� par Springer, 2006

ISBN 10 : 0387340564 ISBN 13 : 9780387340562

Neuf Couverture rigide

Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni

�valuation du vendeur 5 sur 5 �toiles

Etat : New. In. N� de r�f. du vendeur ria9780387340562_new

Contacter le vendeur

Acheter neuf

EUR 227,06

Exp�dition �EUR 13,97
Exp�dition depuis Royaume-Uni vers Etats-Unis

Quantit� disponible : Plus de 20 disponibles

Ajouter au panier

Image fournie par le vendeur

Optimizing the "Drug-Like" Properties of Leads in Drug Discovery

Borchardt, Ronald T.; Kerns, Edward H.; Hageman, Michael J.; Thakker, Dhiren R.; Stevens, James L. (eds.)

Edit� par Springer, New York, 2006

ISBN 10 : 0387340564 ISBN 13 : 9780387340562

Ancien ou d'occasion Couverture rigide

Vendeur : PsychoBabel & Skoob Books, Didcot, Royaume-Uni

�valuation du vendeur 5 sur 5 �toiles

Hardcover. Etat : Very Good. Hardcover (no jacket; printed boards). Includes CD-ROM on inside rear board. Very good condition. Half-title page has partially separated from binding. Boards' leading corners are a little bumped and scuffed. Pages are clear. TA. Used. N� de r�f. du vendeur 510803

Contacter le vendeur

Acheter D'occasion

EUR 234,22

Exp�dition �EUR 14,58
Exp�dition depuis Royaume-Uni vers Etats-Unis

Quantit� disponible : 1 disponible(s)

Ajouter au panier

Image fournie par le vendeur

Optimizing the "Drug-Like" Properties of Leads in Drug Discovery

Ronald Borchardt (u. a.)

Edit� par Springer New York, 2006

ISBN 10 : 0387340564 ISBN 13 : 9780387340562

Neuf Couverture rigide

impression � la demande

Vendeur : preigu, Osnabr�ck, Allemagne

�valuation du vendeur 5 sur 5 �toiles

Contacter le vendeur

Acheter neuf

EUR 181,95

Exp�dition �EUR 70
Exp�dition depuis Allemagne vers Etats-Unis

Quantit� disponible : 5 disponible(s)

Ajouter au panier

Image fournie par le vendeur

"Optimizing the \"Drug-Like\" Properties of Leads in Drug Discovery"

Ronald Borchardt

Edit� par Springer New York, Springer New York Aug 2006, 2006

ISBN 10 : 0387340564 ISBN 13 : 9780387340562

Neuf Couverture rigide

impression � la demande

Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne

�valuation du vendeur 5 sur 5 �toiles

Buch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, �drug-like� properties refer to the molecule�s physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 524 pp. Englisch. N� de r�f. du vendeur 9780387340562

Contacter le vendeur

Acheter neuf

EUR 213,99

Exp�dition �EUR 60
Exp�dition depuis Allemagne vers Etats-Unis

Quantit� disponible : 1 disponible(s)

Ajouter au panier

Image fournie par le vendeur

"Optimizing the \"Drug-Like\" Properties of Leads in Drug Discovery "

Ronald Borchardt

Edit� par Springer New York, Springer New York, 2006

ISBN 10 : 0387340564 ISBN 13 : 9780387340562

Neuf Couverture rigide

Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne

�valuation du vendeur 5 sur 5 �toiles

Buch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, 'drug-like' properties refer to the molecule's physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development. N� de r�f. du vendeur 9780387340562

Contacter le vendeur